Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease that targets the myelin sheaths of peripheral nerve. This rare neurological disorder chiefly presents as symmetric weakness of both proximal and distal muscles, reduced deep tendon reflexes in addition with sensory symptoms. Its sensory predominant variant with clinical feature of sensory ataxia is found in a very small fraction of patients. In the present research article, the participant presented with symmetric progressive weakness of proximal muscles with sensory ataxia and after a panel of investigations, she was diagnosed to be a case of sensory predominant CIDP according to EFNS/PNS diagnostic criteria (2010). Prednisolone is used as first line treatment of typical CIDP but there is less evidence in literature about its use in sensory predominant CIDP. There was also very few evidences where steroid was used as single agent for its treatment purpose. High pulse dose therapy versus low daily dose steroid is also an field of further research regarding treatment options. Regarding efficacy and cos-effectiveness, comparison between immunoglobulin and oral prednisolone in the treatment of CIDP is also a field of future work up .This review highlights how minimal daily dose of oral prednisolone is proven to be efficacious in sensory predominant CIDP .